Cisplatin-based chemotherapy is the standard treatment for bladder urothelial carcinoma
(UC). Most patients experience chemoresistance, the primary cause of treatment failure …

After chemotherapy for the treatment of metastatic bladder urothelial carcinoma (UC), most
patients inevitably encounter drug resistance and resultant treatment failure …

Urothelial carcinoma (UC) comprises the majority of bladder cancers. Standard platinum-
based chemotherapy has a response rate of approximately 50%, but drug resistance …

Background/Aim: Activation of the ubiquitin-proteasome system (UPS) has been shown to
be associated with drug resistance in cancer. Using bladder cancer cells, we investigated …

Background: The inhibition of ubiquitin-specific proteases (USPs) is a novel and promising
direction in the development of molecularly targeted therapies in oncology. The aim of the …

Therapeutic efficacy of cisplatin-based treatment of late stage urothelial carcinoma (UC) is
limited by chemoresistance. To elucidate underlying mechanisms and to develop new …

Cisplatin-based chemotherapy is the primary treatment for metastatic bladder urothelial
carcinoma. However, the response rate is only 40–65%. This study investigated the anti …

Cisplatin (CisPt) is frequently used in the therapy of urothelial carcinoma (UC). Its
therapeutic efficacy is limited by inherent or acquired drug resistance. Here, we …

PURPOSE: Therapeutically induced autophagic cell death has been proven to be effective
in cases of solid tumors. The dual phosphatidylinositol 3-kinase (PI3K) and mammalian …

Mucin 1 C‐terminal subunit (MUC1‐C) has been introduced as a key regulator for acquiring
drug resistance in various cancers, but the functional role of MUC1‐C in urothelial …